arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Savara Inc

SVRA
$5.82 ▲ +0.01 (+0.17%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
81 Visible periods
27 Metrics
Peer-ranked Benchmarks
Price Chart
35
Health
Poor
Neutral
auto_awesome

Analytical Summary

Savara Inc shows mixed fundamentals. On the positive side, Debt to Equity remains strong. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap $1.5B
Dividend Yield
Revenue Growth None
Op. Margin
ROIC -14.9%
FCF / Share $-0.13
Trailing P/E
Price / Book 6.8x
FCF Yield
Debt / Equity 0.17
info Valuation on last close. End-of-day price, Aug 7, 2026.

81-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
↓ -100.0%
Net Income Profit after all expenses
$-37.28M
↓ -40.0%
FCF / Share Free cash flow per share
$-0.13
↓ -3.9%
Long-Term Debt Long-term obligations
$30.07M
↑ +0.5%
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
15
Financial Health
48
Cash Quality
57

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 31 years · 81 quarters